Previous close | 2.6000 |
Open | 2.2900 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 22.50 |
Expiry date | 2025-01-17 |
Day's range | 1.8000 - 2.6000 |
Contract range | N/A |
Volume | |
Open interest | 638 |
Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Whitefort Capital wants biopharmaceutical firm Arbutus to stop issuing stock. Shah Capital ended a proxy campaign against biotech Novavax.
The Biden administration is reportedly in talks with vaccine makers Moderna (MRNA) and Pfizer (PFE) to develop bird flu vaccines over increasing fears of widespread transmission of the infection.